| Progressive multiple sclerosis: from pathophysiology to therapeutic strategies S Faissner, JR Plemel, R Gold, VW Yong Nature reviews drug discovery 18 (12), 905-922, 2019 | 345 | 2019 |
| Neurological events reported after COVID‐19 vaccines: an analysis of vaccine adverse event reporting system JA Frontera, AA Tamborska, MF Doheim, D Garcia‐Azorin, H Gezegen, ... Annals of Neurology 91 (6), 756-771, 2022 | 97 | 2022 |
| Multi-target-directed phenol–triazole ligands as therapeutic agents for Alzheimer's disease MR Jones, E Mathieu, C Dyrager, S Faissner, Z Vaillancourt, KJ Korshavn, ... Chemical science 8 (8), 5636-5643, 2017 | 95 | 2017 |
| Efficacy and safety of the newer multiple sclerosis drugs approved since 2010 S Faissner, R Gold CNS drugs 32 (3), 269-287, 2018 | 89 | 2018 |
| Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis R Hoepner, S Faissner, A Salmen, R Gold, A Chan Journal of central nervous system disease 6, JCNSD. S14049, 2014 | 82 | 2014 |
| Progressive multiple sclerosis: latest therapeutic developments and future directions S Faissner, R Gold Therapeutic advances in neurological disorders 12, 1756286419878323, 2019 | 72 | 2019 |
| Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke G Tsivgoulis, AH Katsanos, VK Sharma, C Krogias, R Mikulik, ... Neurology 86 (12), 1103-1111, 2016 | 71 | 2016 |
| Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic S Faissner, M Mishra, DK Kaushik, J Wang, Y Fan, C Silva, G Rauw, ... Nature communications 8 (1), 1990, 2017 | 60 | 2017 |
| Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment S Faissner, R Hoepner, C Lukas, A Chan, R Gold, G Ellrichmann Therapeutic advances in neurological disorders 8 (5), 233-238, 2015 | 55 | 2015 |
| Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model AT Wilmes, S Reinehr, S Kühn, X Pedreiturria, L Petrikowski, S Faissner, ... Journal of neuroinflammation 15 (1), 1-17, 2018 | 48 | 2018 |
| Oral therapies for multiple sclerosis S Faissner, R Gold Cold Spring Harbor perspectives in medicine 9 (1), a032011, 2019 | 44 | 2019 |
| Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease? S Faissner, Y Mahjoub, M Mishra, S Haupeltshofer, JN Hahn, R Gold, ... Multiple Sclerosis Journal 24 (12), 1543-1556, 2018 | 40 | 2018 |
| Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity B Ambrosius, S Faissner, K Guse, M von Lehe, T Grunwald, R Gold, ... Journal of neuroinflammation 14, 1-10, 2017 | 39 | 2017 |
| Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses S Faissner, J Nikolayczik, A Chan, K Hellwig, R Gold, MS Yoon, ... Journal of neurology 263, 1092-1098, 2016 | 38 | 2016 |
| COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis S Faissner, D Richter, U Ceylan, C Schneider-Gold, R Gold Journal of neurology 269 (4), 1774-1775, 2022 | 34 | 2022 |
| Immunoadsorption in patients with neuromyelitis optica spectrum disorder S Faissner, J Nikolayczik, A Chan, R Gold, MS Yoon, A Haghikia Therapeutic advances in neurological disorders 9 (4), 281-286, 2016 | 34 | 2016 |
| Statin pretreatment and microembolic signals in large artery atherosclerosis A Safouris, C Krogias, VK Sharma, AH Katsanos, S Faissner, ... Arteriosclerosis, thrombosis, and vascular biology 37 (7), 1415-1422, 2017 | 33 | 2017 |
| Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis S Haupeltshofer, T Leichsenring, S Berg, X Pedreiturria, SC Joachim, ... Proceedings of the National Academy of Sciences 116 (51), 25860-25869, 2019 | 31 | 2019 |
| Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis R Hoepner, S Faissner, A Klasing, R Schneider, I Metz, B Bellenberg, ... Neuroimmunology & Neuroinflammation 2 (3), e85, 2015 | 31 | 2015 |
| “Liberation treatment” for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free G Tsivgoulis, S Faissner, K Voumvourakis, AH Katsanos, N Triantafyllou, ... Brain and behavior 5 (1), e00297, 2015 | 30 | 2015 |
Christos KrogiasDept. of Neurology, St. Josef-Hospital, Ruhr University Bochum在 rub.de 的电子邮件经过验证
